Major stock indexes closed lower on Friday, after the week saw a flurry of corporate earnings reports from major tech firms, including Alphabet and Amazon. The healthcare industry also had its fair ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

From the impact of the new Trump Administration on research and development to advancements in brain health, PBM reform, and ...

Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Merck & Co. (MRK) stock lost over 9% yesterday on announcing a temporary shipment halt of its Gardasil vaccine to China. The ...

The stock markets in the US opened higher on February 4 as investors remained cautious about China’s stance on the Trump ...